Hal W. Hirte
Impact in
- Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.5%
- PARP inhibition in cancer therapy
Papers in
-
- Ovarian cancer diagnosis and treatment 58
- Oncology 71
- HER2/EGFR in Cancer Research 15
- Cancer Treatment and Pharmacology 11
- Co-authors
- Amit M. OzaSilvia BacchettiHelen MackaySébastien J. HotteHeinz‐Josef LenzKaren A. GelmonLillian L. SiuEuan Macpherson
- Journals
- Journal of Clinical Oncology (55 papers)Annals of Oncology (12 papers)Gynecologic Oncology (12 papers)Investigational New Drugs (11 papers)Clinical Cancer Research (5 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Hal W. Hirte
154 papers receiving 7.9k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Reproductive Medicine 2.3k
- Oncology 3.7k
- Obstetrics and Gynecology 587
- Cancer Research 977
- Pathology and Forensic Medicine 1.0k
Countries citing papers authored by Hal W. Hirte
This map shows the geographic impact of Hal W. Hirte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hal W. Hirte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hal W. Hirte more than expected).
Fields of papers citing papers by Hal W. Hirte
This network shows the impact of papers produced by Hal W. Hirte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hal W. Hirte. The network helps show where Hal W. Hirte may publish in the future.
Co-authors
The 25 scholars most cited alongside Hal W. Hirte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 6 | |
| 2 | 2021 | 9 | |
| 3 | 2021 | 3 | |
| 4 | 2018 | 43 | |
| 5 | 2017 | 21 | |
| 6 | 2015 | 62 | |
| 7 | 2015 | 20 | |
| 8 | 2014 | 7 | |
| 9 | 2014 | 43 | |
| 10 | Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial | 2013 | 75 |
| 11 | 2011 | 119 | |
| 12 | 2008 | 137 | |
| 13 | 2008 | 15 | |
| 14 | A Phase 2 study of AZD2171 in recurrent or persistent ovarian, peritoneal or fallopian tube cancer. A study of the PMH, Chicago, and California Phase II Consortia | 2007 | 1 |
| 15 | Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers | 2007 | 11 |
| 16 | 2007 | 25 | |
| 17 | 2006 | 8 | |
| 18 | 2005 | 77 | |
| 19 | 2004 | 22 | |
| 20 | 2002 | 21 |
About Hal W. Hirte
Hal W. Hirte is a scholar working on Reproductive Medicine, Oncology, Obstetrics and Gynecology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 156 papers that have together received 8.1k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (58 papers), Renal cell carcinoma treatment (17 papers), HER2/EGFR in Cancer Research (15 papers), Intraperitoneal and Appendiceal Malignancies (15 papers), Lung Cancer Treatments and Mutations (12 papers), Cancer therapeutics and mechanisms (11 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Cancer Treatment and Pharmacology (11 papers). The work is most often cited by research in Reproductive Medicine (2.3k citations), Oncology (3.7k citations), Obstetrics and Gynecology (587 citations), Cancer Research (977 citations) and Pathology and Forensic Medicine (1.0k citations). Hal W. Hirte has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Amit M. Oza, Silvia Bacchetti, Helen Mackay, Sébastien J. Hotte, Heinz‐Josef Lenz, Karen A. Gelmon, Lillian L. Siu, Euan Macpherson, Malcolm J. Moore and Gini F. Fleming. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Gynecologic Oncology, Investigational New Drugs and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.